Overall survival (OS) of EGFR mutation-positive non-small cell lung cancer (NSCLC) patients: Real-world treatment patterns of 1,660 Japanese patients (pts).

被引：0
|
作者：
Kazushi, Yoshida
Inoue, Akira
Sugawara, Shunichi
Murakami, Shuji
Saka, Hideo
Morita, Satoshi
Kim, Young Hak
Imamura, Fumio
Takeda, Koji
Nakagawa, Kazuhiko
Takeda, Masayuki
Atagi, Shinji
Hasegawa, Yoshikazu
Yamamoto, Nobuyuki
Katakami, Nobuyuki
Yoshioka, Hiroshige
Iwamoto, Yasuo
Okamoto, Isamu
Seto, Takashi
Ohe, Yuichiro
机构：
[1] Natl Canc Ctr, Tokyo, Japan
[2] Tohoku Univ Hosp, Sendai, Miyagi, Japan
[3] Sendai Kousei Hosp, Sendai, Miyagi, Japan
[4] Kanagawa Canc Ctr, Dept Thorac Oncol, Yokohama, Kanagawa, Japan
[5] Nagoya Med Ctr, Nagoya, Aichi, Japan
[6] Kyoto Univ, Grad Sch Med, Dept Biomed Stat & Bioinformat, Kyoto, Japan
[7] Kyoto Univ Hosp, Kyoto, Japan
[8] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Pulm Oncol, Osaka, Japan
[9] Osaka City Gen Hosp, Dept Med Oncol, Osaka, Japan
[10] Kinki Univ, Sch Med, Osaka, Japan
[11] Kinki Univ, Fac Med, Dept Med Oncol, Osaka, Japan
[12] Kinki Chuo Chest Med Ctr, Osaka, Japan
[13] Kinki Univ, Sakai Hosp, Sch Med, Sakai, Osaka, Japan
[14] Wakayama Med Univ, Dept Internal Med 3, Wakayama, Japan
[15] Inst Biomed Res & Innovat, Div Integrated Oncol, Kobe, Hyogo, Japan
[16] Kurashiki Cent Hosp, Kurashiki, Okayama, Japan
[17] Hiroshima City Hosp, Dept Med Oncol, Hiroshima, Japan
[18] Kyushu Univ Hosp, Fukuoka, Japan
[19] Natl Kyushu Canc Ctr, Fukuoka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e20503
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20503
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Is afatinib a treatment option for brain metastases in patients with EGFR mutation-positive non-small cell lung cancer?
    Watanabe, Satomi
    Hayashi, Hidetoshi
    Nakagawa, Kazuhiko
    ANNALS OF TRANSLATIONAL MEDICINE, 2016, 4 (11)
  • [22] FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer
    Kazandjian, Dickran
    Blumenthal, Gideon M.
    Yuan, Weishi
    He, Kun
    Keegan, Patricia
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2016, 22 (06) : 1307 - 1312
  • [23] Overall survival of patients with EGFR mutation-positive non-small-cell lung cancer treated with erlotinib, gefitinib or afatinib under drug programmes in Poland - real-world data
    Brzozowska, Melania
    Wierzba, Waldemar
    Szafraniec-Burylo, Sylwia
    Czech, Marcin
    Majkut, Gabriela
    Polowinczak-Przybylek, Joanna
    Potemski, Piotr
    Sliwczynski, Andrzej
    ARCHIVES OF MEDICAL SCIENCE, 2021, 17 (06) : 1618 - 1627
  • [24] Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer
    Lilenbaum, Rogerio A.
    Horn, Leora A.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2016, 14 (5.5): : 672 - 674
  • [25] Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer
    Igawa, Satoshi
    Ono, Taihei
    Kasajima, Masashi
    Kusuhara, Seiichiro
    Otani, Sakiko
    Fukui, Tomoya
    Yokoba, Masanori
    Kubota, Masaru
    Katagiri, Masato
    Mitsufuji, Hisashi
    Sasaki, Jiichiro
    Naoki, Katsuhiko
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (06) : 1906 - 1914
  • [26] Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer
    Satoshi Igawa
    Taihei Ono
    Masashi Kasajima
    Seiichiro Kusuhara
    Sakiko Otani
    Tomoya Fukui
    Masanori Yokoba
    Masaru Kubota
    Masato Katagiri
    Hisashi Mitsufuji
    Jiichiro Sasaki
    Katsuhiko Naoki
    Investigational New Drugs, 2020, 38 : 1906 - 1914
  • [27] Testing patterns and outcomes of different EGFR-positive metastatic non-small cell lung cancer (NSCLC) patients in a Canadian real-world setting
    Boyne, D. J.
    Jarada, T.
    Yusuf, A.
    O'Sullivan, D. E.
    Hu, L. X. Y.
    Brenner, D. R.
    Abbie, E.
    Rose, J. B.
    Eaton, K.
    Ewara, E. M.
    Cheung, W. Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S56 - S56
  • [28] Real-world first-line afatinib for advanced EGFR mutation-positive non-small cell lung cancer in Korea: updated survival data
    Choi, Juwhan
    Choi, Chang Min
    Chang, Yoon Soo
    Lee, Kye Young
    Kim, Seung Joon
    Yang, Sei Hoon
    Ryu, Jeong Seon
    Lee, Jeong Eun
    Lee, Shin Yup
    Park, Ji Young
    Kim, Young-Chul
    Oh, In-Jae
    Jung, Chi Young
    Lee, Sang Hoon
    Yoon, Seong Hoon
    Lee, Sung Yong
    Jang, Tae Won
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (11) : 2275 - 2282
  • [29] ASTRIS: A real world treatment study of osimertinib in patients (pts) with EGFR T790M positive non-small cell lung cancer (NSCLC).
    De Marinis, Filippo
    Cho, Byoung Chul
    Kim, Dong-Wan
    Kim, Sang-We
    Hochmair, Maximilian J.
    Metro, Giulio
    Vansteenkiste, Johan F.
    Vicente, David
    Solomon, Benjamin J.
    Cheema, Parneet K.
    Freitas, Helano C.
    Provencio, Mariano
    Chen, Yuh-Min
    Wu, Yi-Long
    Milner, Alvin
    Rigas, James R.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC)
    Passaro, A.
    Yang, J. C.
    Ahn, M.
    Dickgreber, N. J.
    Halmos, B.
    Hirsh, V.
    Hochmair, M. J.
    Levy, B. P.
    de Marinis, F.
    Mok, T.
    O'Byrne, K.
    Okamoto, I.
    Schuler, M.
    Sebastian, M.
    Shah, R.
    Tan, E.
    Yamamoto, N.
    Maerten, A.
    Wind, S.
    Carbone, D. P.
    ANNALS OF ONCOLOGY, 2015, 26 : 77 - 77
12345